Purchase this article with an account.
F. Lu, R. Adelman; Compare and Evaluate the Efficacy and Safety of Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib Sodium in the Treatment of Choroidal Neovascularization in a Rat Model. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1461.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the efficacy and safety of Intravitreal Injection of bevacizumab ( Avastin®), pegaptanib sodium (Macugen®) and ranibizumab (LucentisTM) in the treatment of choroidal neovascularization (CNV) in a rat model.
Multiple CNV lesions were induced by laser photocoagulation of the retina in Norway-Brown rats. After 3 weeks, 14 rats were divided into three groups and received intravitreal injection of bevacizumab, pegaptanib sodium and ranibizumab in different dosage respectively. Some of the lesions received second treatment on day 14. The lesions were evaluated by fluorescein angiography 1, 7, 14 and 28 days later to assess the efficacy of these medications.
The dosage of bevacizumab in the treatment of CNV in rat model ranged from 0.025mg to 0.25mg. All of them did not show any effect in stopping the angiographic leakage in fluorescein angiography through day 28. Ranibizumab (0.012mg-0.06mg) and pegaptanib sodium (0.01mg) did not stop the leakage of CNV either. Second treatment of bevacizumab and pegaptanib sodium did not affect. There was no local and systemic side effect observed in rats.
All of these three anti VEGF agents did not show any treatment effect in stopping laser-induced CNV leakage in rat. Our previous experiment with ranibizumab in monkeys resulted in significant decrease in leakage. The difference might be because ranibizumab is a humanized antibody and there is a difference between human and rat.
This PDF is available to Subscribers Only